

# Stephen H Friend

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2792548/publications.pdf>

Version: 2024-02-01

93  
papers

45,457  
citations

34105

52  
h-index

38395

95  
g-index

102  
all docs

102  
docs citations

102  
times ranked

47251  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression profiling predicts clinical outcome of breast cancer. <i>Nature</i> , 2002, 415, 530-536.	27.8	8,655
2	A Gene-Expression Signature as a Predictor of Survival in Breast Cancer. <i>New England Journal of Medicine</i> , 2002, 347, 1999-2009.	27.0	5,759
3	Functional Characterization of the <i>S.cerevisiae</i> Genome by Gene Deletion and Parallel Analysis. <i>Science</i> , 1999, 285, 901-906.	12.6	3,761
4	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	30.7	3,596
5	A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. <i>Nature</i> , 1986, 323, 643-646.	27.8	2,853
6	Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. <i>Molecular Cell</i> , 2013, 49, 359-367.	9.7	2,734
7	Functional Discovery via a Compendium of Expression Profiles. <i>Cell</i> , 2000, 102, 109-126.	28.9	2,412
8	Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. <i>Nature</i> , 1988, 334, 124-129.	27.8	1,533
9	Genetics of gene expression surveyed in maize, mouse and man. <i>Nature</i> , 2003, 422, 297-302.	27.8	1,401
10	Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. <i>Nature Biotechnology</i> , 2001, 19, 342-347.	17.5	1,225
11	Signaling and Circuitry of Multiple MAPK Pathways Revealed by a Matrix of Global Gene Expression Profiles. <i>Science</i> , 2000, 287, 873-880.	12.6	835
12	Integrating Genetic Approaches into the Discovery of Anticancer Drugs. <i>Science</i> , 1997, 278, 1064-1068.	12.6	699
13	Drug target validation and identification of secondary drug target effects using DNA microarrays. <i>Nature Medicine</i> , 1998, 4, 1293-1301.	30.7	635
14	Predictive, personalized, preventive, participatory (P4) cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 184-187.	27.6	628
15	Gene expression changes associated with progression and response in chronic myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2794-2799.	7.1	525
16	Widespread aneuploidy revealed by DNA microarray expression profiling. <i>Nature Genetics</i> , 2000, 25, 333-337.	21.4	454
17	The mPower study, Parkinson disease mobile data collected using ResearchKit. <i>Scientific Data</i> , 2016, 3, 160011.	5.3	439
18	Strengths and weaknesses in the current applications of expression profiling. <i>Nature Genetics</i> , 1999, 23, 20-20.	21.4	425

#	ARTICLE	IF	CITATIONS
19	Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer. New England Journal of Medicine, 1996, 334, 143-149.	27.0	408
20	Germline Mutations of the p53 Tumor-Suppressor Gene in Children and Young Adults with Second Malignant Neoplasms. New England Journal of Medicine, 1992, 326, 1309-1315.	27.0	365
21	Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nature Methods, 2015, 12, 623-630.	19.0	282
22	Analysis of 589,306 genomes identifies individuals resilient to severe Mendelian childhood diseases. Nature Biotechnology, 2016, 34, 531-538.	17.5	273
23	A network view of disease and compound screening. Nature Reviews Drug Discovery, 2009, 8, 286-295.	46.4	269
24	Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nature Genetics, 2012, 44, 841-847.	21.4	252
25	Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nature Genetics, 1993, 5, 124-129.	21.4	243
26	Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes. Science Translational Medicine, 2017, 9, .	12.4	240
27	Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Network Open, 2020, 3, e200265.	5.9	236
28	A Cell Proliferation Signature Is a Marker of Extremely Poor Outcome in a Subpopulation of Breast Cancer Patients. Cancer Research, 2005, 65, 4059-4066.	0.9	233
29	Oncogenes and Tumor-Suppressing Genes. New England Journal of Medicine, 1988, 318, 618-622.	27.0	224
30	Pleuropulmonary blastoma: A marker for familial disease. Journal of Pediatrics, 1996, 128, 220-224.	1.8	210
31	Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods, 2016, 13, 310-318.	19.0	209
32	Cancer Biomarkers--An Invitation to the Table. Science, 2006, 312, 1165-1168.	12.6	201
33	Genetic Selection of Peptide Inhibitors of Biological Pathways. Science, 1999, 285, 591-595.	12.6	185
34	Toxicogenomics and drug discovery: will new technologies help us produce better drugs?. Nature Reviews Drug Discovery, 2002, 1, 84-88.	46.4	176
35	Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions. Molecular and Cellular Biology, 2006, 26, 9377-9386.	2.3	176
36	p53: a glimpse at the puppet behind the shadow play. Science, 1994, 265, 334-335.	12.6	153

#	ARTICLE	IF	CITATIONS
37	The Use of Smartphones for Health Research. <i>Academic Medicine</i> , 2017, 92, 157-160.	1.6	138
38	Crowdsourcing biomedical research: leveraging communities as innovation engines. <i>Nature Reviews Genetics</i> , 2016, 17, 470-486.	16.3	137
39	Functional analysis of human MLH1 mutations in <i>Saccharomyces cerevisiae</i> . <i>Nature Genetics</i> , 1998, 19, 384-389.	21.4	136
40	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , The, 2017, 18, 132-142.	10.7	124
41	A rapid PCR fidelity assay. <i>Nucleic Acids Research</i> , 1994, 22, 3259-3260.	14.5	111
42	Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors. <i>Cancer Discovery</i> , 2015, 5, 118-123.	9.4	109
43	Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 181re1.	12.4	108
44	Mining the NCI Anticancer Drug Discovery Databases: Genetic Function Approximation for the QSAR Study of Anticancer Ellipticine Analogues. <i>Journal of Chemical Information and Computer Sciences</i> , 1998, 38, 189-199.	2.8	107
45	Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. <i>Nature Genetics</i> , 2013, 45, 1121-1126.	21.4	102
46	Prediction of human population responses to toxic compounds by a collaborative competition. <i>Nature Biotechnology</i> , 2015, 33, 933-940.	17.5	88
47	Mining the National Cancer Institute Anticancer Drug Discovery Database: Cluster Analysis of Ellipticine Analogs with p53-Inverse and Central Nervous System-Selective Patterns of Activity. <i>Molecular Pharmacology</i> , 1998, 53, 241-251.	2.3	83
48	Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling. <i>PLoS Computational Biology</i> , 2013, 9, e1003047.	3.2	76
49	Discrete charge calculations of potentiometric titrations for globular proteins: Sperm whale myoglobin, hemoglobin alpha chain, cytochrome c. <i>Biochemical and Biophysical Research Communications</i> , 1978, 81, 416-421.	2.1	69
50	Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting. <i>PLoS ONE</i> , 2011, 6, e20090.	2.5	68
51	Potential of the Synthetic Lethality Principle. <i>Science</i> , 2013, 342, 809-811.	12.6	67
52	Microarrays—the 21st century divining rod?. <i>Nature Medicine</i> , 2001, 7, 658-659.	30.7	57
53	Developing predictive molecular maps of human disease through community-based modeling. <i>Nature Genetics</i> , 2012, 44, 127-130.	21.4	54
54	First, design for data sharing. <i>Nature Biotechnology</i> , 2016, 34, 377-379.	17.5	51

#	ARTICLE	IF	CITATIONS
55	Structure and expression of the <i>Xenopus</i> retinoblastoma gene. <i>Developmental Biology</i> , 1992, 153, 141-149.	2.0	47
56	Opening Up to Precompetitive Collaboration. <i>Science Translational Medicine</i> , 2010, 2, 52cm26.	12.4	47
57	The Magic of Microarrays. <i>Scientific American</i> , 2002, 286, 44-53.	1.0	46
58	Clues from the resilient. <i>Science</i> , 2014, 344, 970-972.	12.6	44
59	Leveraging Crowdsourcing to Facilitate the Discovery of New Medicines. <i>Science Translational Medicine</i> , 2011, 3, 88mr1.	12.4	42
60	Global optimization of somatic variant identification in cancer genomes with a global community challenge. <i>Nature Genetics</i> , 2014, 46, 318-319.	21.4	42
61	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. <i>Clinical Cancer Research</i> , 2014, 20, 265-272.	7.0	36
62	Challenges in identifying cancer genes by analysis of exome sequencing data. <i>Nature Communications</i> , 2016, 7, 12096.	12.8	34
63	Breast cancer information on the web. <i>Nature Genetics</i> , 1995, 11, 238-239.	21.4	33
64	Metcalfe's law and the biology information commons. <i>Nature Biotechnology</i> , 2013, 31, 297-303.	17.5	32
65	Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. <i>Clinical Cancer Research</i> , 2013, 19, 4315-4325.	7.0	32
66	Unlocking stress and forecasting its consequences with digital technology. <i>Npj Digital Medicine</i> , 2019, 2, 75.	10.9	32
67	The NIH BD2K center for big data in translational genomics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1143-1147.	4.4	30
68	Emerging Uses for Genomic Information in Drug Discovery. <i>New England Journal of Medicine</i> , 1998, 338, 125-126.	27.0	28
69	An accelerated pathway for targeted cancer therapies. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 79-80.	46.4	28
70	A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. <i>PLoS Computational Biology</i> , 2016, 12, e1004890.	3.2	28
71	Breast cancer susceptibility testing: realities in the post-genomic era. <i>Nature Genetics</i> , 1996, 13, 16-17.	21.4	25
72	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease 1. <i>Journal of Parkinson's Disease</i> , 2015, 5, 581-594.	2.8	25

#	ARTICLE	IF	CITATIONS
73	Cheap DNA arrays—it's not all smoke and mirrors. <i>Nature Biotechnology</i> , 1999, 17, 953-953.	17.5	24
74	The Precompetitive Space: Time to Move the Yardsticks. <i>Science Translational Medicine</i> , 2011, 3, 76cm10.	12.4	24
75	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. <i>Nature Genetics</i> , 2013, 45, 468-469.	21.4	24
76	Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. <i>Nature Medicine</i> , 1997, 3, 962-963.	30.7	21
77	Secondary breast cancer in patients presenting with osteosarcoma: Possible involvement of germline p53 mutations. <i>Medical and Pediatric Oncology</i> , 1994, 23, 354-358.	1.0	16
78	The Prostate Cancer DREAM Challenge: A Community-Wide Effort to Use Open Clinical Trial Data for the Quantitative Prediction of Outcomes in Metastatic Prostate Cancer. <i>Oncologist</i> , 2015, 20, 459-460.	3.7	14
79	The cancer predisposition revolution. <i>Science</i> , 2016, 352, 1052-1053.	12.6	14
80	App-enabled trial participation: Tectonic shift or tepid rumble?. <i>Science Translational Medicine</i> , 2015, 7, 297ed10.	12.4	12
81	An Alternative to the Light Touch Digital Health Remote Study: The Stress and Recovery in Frontline COVID-19 Health Care Workers Study. <i>JMIR Formative Research</i> , 2021, 5, e32165.	1.4	11
82	The inconvenience of data of convenience: computational research beyond post-mortem analyses. <i>Nature Methods</i> , 2017, 14, 937-938.	19.0	9
83	Disrupting the power balance between doctors and patients in the digital era. <i>The Lancet Digital Health</i> , 2021, 3, e142-e143.	12.3	8
84	Using Patient-Initiated Study Participation in the Development of Evidence for Personalized Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 6651-6657.	7.0	7
85	Screening for cancer susceptibility in children. <i>Current Opinion in Pediatrics</i> , 1994, 6, 46-51.	2.0	6
86	Accelerating drug discovery: Open source cancer cell biology?. <i>Cancer Cell</i> , 2006, 10, 349-351.	16.8	6
87	Stress-related consequences of the coronavirus disease 2019 pandemic on symptoms of Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 1511-1516.	1.6	6
88	A simple recipe for drug interaction networks earns its stars. <i>Nature Genetics</i> , 2006, 38, 405-406.	21.4	5
89	Tempus edax rerum. <i>Cell</i> , 1991, 66, 189-190.	28.9	3
90	Sibling rivalry, arrested development and chromosomal mayhem. <i>Nature Genetics</i> , 1998, 19, 9-10.	21.4	2

#	ARTICLE	IF	CITATIONS
91	Alfred Knudson: The importance of a visionary who enables scientists. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 326-328.	2.8	2
92	Laboratoryâ€“clinical interface. <i>Cancer</i> , 1993, 71, 3219-3221.	4.1	0
93	Social Interactomes for Enabling Research Communities. <i>Cancer Discovery</i> , 2014, 4, 1265-1268.	9.4	0